Novo Nordisk Submits NDA For Insulin Co-formulation In Japan
This article was originally published in PharmAsia News
Executive Summary
Novo Nordisk A/S submits a new drug application in Japan for co-formulation of degludec/aspart insulin for type 1 and type 2 diabetes.